Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Hodgkin Disease 2Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Mantle-Cell 1Liposarcoma, Myxoid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Hematologic Neoplasms 1Graft vs Host Disease 1Chondrosarcoma 1Anemia, Refractory, with Excess of Blasts 1

Interventions

pazopanib 2sintilimab 1sapanisertib 1pembrolizumab 1itacitinib 1baricitinib 1Trabectedin 1Radiotherapy, Intensity-Modulated 1Polymerase Chain Reaction 1Neoadjuvant Therapy 1INCB039110 1Gene Expression Profiling 1Doxorubicin 1Docetaxel 1Blotting, Western 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Histiocytoma, Malignant Fibrous × INCB039110 × Clear all
NCT03670069 2024-05-08

Itacitinib in Treating Patients With Refractory Metastatic/Advanced Sarcomas

Fred Hutchinson Cancer Center

Phase 1 Terminated
27 enrolled
Sarcoma

Chondrosarcoma, Leiomyosarcoma, Sarcoma, Sarcoma, Synovial, Liposarcoma, Myxoid, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡